Skip to content
The Policy VaultThe Policy Vault

azacitidine — CareFirst (Caremark)

Acute myeloid leukemia (AML)

Initial criteria

  • Authorization may be granted for the treatment of acute myeloid leukemia (AML).

Reauthorization criteria

  • Authorization may be granted for continued treatment when there is no evidence of unacceptable toxicity or disease progression while on the current regimen.

Approval duration

12 months